Key result
Pretreatment with pumpkin carotenoid extract significantly reduced doxorubicin-induced myocardial damage in rats, lowering the doxorubicin damage score from 5 to 1.75 (p=0.013).
Why the study?
Cardiotoxicity is the leading adverse effect limiting clinical use of doxorubicin, and carotenoids may play a protective role.
Does pretreatment with pumpkin carotenoids prevent doxorubicin-induced cardiotoxicity in an animal model?
Population
Animals distributed in 8 groups
Comparison
Pumpkin carotenoids vs commercially available antioxidant preparation (CardiofortIN), controls, and doxorubicin
Design
In vivo study
Authors
Loading...
May support carotenoid cardioprotection in doxorubicin animal models; leaves open translation to human cancer patients.
Does pretreatment with pumpkin carotenoids prevent doxorubicin-induced cardiotoxicity in an animal model?
Absolute Event Rate: 1.75% vs 5%
p-value: p=0.013
Pumpkin carotenoids demonstrate promising cardioprotective effects against doxorubicin-induced cardiotoxicity in an animal model, likely mediated through inhibition of oxidative stress.
Bosanac et al. (2023) studied Doxorubicin-induced cardiotoxicity (n=80). Pumpkin carotenoids extract vs. Doxorubicin alone was evaluated on Doxorubicin damage score (DDS) (p=0.013). Pretreatment with pumpkin carotenoid extract significantly reduced doxorubicin-induced myocardial damage in rats, lowering the doxorubicin damage score from 5 to 1.75 (p=0.013).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: